Pioneers in neutralizing GDF-15 to reverse key immune resistance mechanisms to cancer therapies
Reinstating efficient anti-tumor activity and resetting responses to checkpoint inhibition by reenabling immune cell activation and tumor infiltration
Led by an international team of proven drug developers to treat cancer and cachexia
Catalyzing
immunotherapy
CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors.
Our latest news &
where to connect
IASLC 2026 World Conference on Lung Cancer
September 12 – September 15, 2026
Seoul, South Korea